Neuphoria Therapeutics Inc.NEUPEarnings & Financial Report
Neuphoria Therapeutics Inc is a clinical-stage biopharmaceutical company focused on researching and developing innovative targeted therapies for unmet medical needs in neurological and psychiatric conditions, including anxiety, treatment-resistant depression, and other central nervous system disorders. Its core R&D efforts prioritize delivering safer, more effective treatment options for patient groups with limited existing care alternatives.
NEUP Q3 2025 Key Financial Metrics
Revenue
$15.0M
Gross Profit
N/A
Operating Profit
$12.0M
Net Profit
$11.3M
Gross Margin
N/A
Operating Margin
79.8%
Net Margin
75.1%
YoY Growth
N/A
EPS
$6.55
Financial Flow
Neuphoria Therapeutics Inc. Q3 2025 Financial Summary
Neuphoria Therapeutics Inc. reported revenue of $15.0M for Q3 2025, with a net profit of $11.3M (75.1% margin). Cost of goods sold was N/A.
Key Financial Metrics
| Total Revenue | $15.0M |
|---|---|
| Net Profit | $11.3M |
| Gross Margin | N/A |
| Operating Margin | 79.8% |
| Report Period | Q3 2025 |
Neuphoria Therapeutics Inc. Quarterly Revenue & Net Profit History
Neuphoria Therapeutics Inc. results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 2025 | $15.0M | — | $11.3M | 75.1% |
| Q2 2025 | $662.7K | — | $-1.9M | -293.2% |
Income Statement
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Revenue | $662715 | $15.0M |
| YoY Growth | N/A | N/A |
Balance Sheet
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Assets | $18.2M | $30.7M |
| Liabilities | $4.4M | $4.7M |
| Equity | $13.7M | $26.0M |
Cash Flow
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Operating CF | $-3.4M | $11.5M |